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Screening For Pre-Invasive Disease Of The 
Cervix
Protocol varies on the age of entry into the 
screening programme. According to American 
Society for Colposcopy and Cervical Pathology 
(ASCCP), cervical cancer screening should 
6
begin at age 21.  According to ASCCP, women 
under the age of 21 should not be screened 
regardless of the age of sexual initiation or other 
6
risk factors.  In the newly released American 
College of Obstetrics and Gynecology (ACOG) 
7
guideline,  women aged 21-29 should only have 
cytology screening every 3 years. HPV testing 
shouldn't be conducted in these women. While 
those between ages 30 through 65, should have 
cytology screening with human papillomavirus 
(HPV) co-testing every 5 years. A high-risk 
HPV DNA test is the preferred recommendation.  
Cytology alone every 3 years is also acceptable 
in these women. However, HPV testing alone is 
7
not recommended.
After age 65, future screening recommendations 
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ABSTRACT:
Cervical cancer ranks as the third most common cancer after breast (1.38 million cases) and 
1
colorectal cancer (0.57 million cases).  In 2008, about 529,000 new cases of cervical cancer were 
2
diagnosed globally.  This disease is the fourth most common cause of cancer-death (275,000 deaths) 
ranking below breast (458 000 deaths), lung (427 000 deaths) and colorectal cancer (288 000 
1
deaths).  Eighty-six percent of all cervical cancers and 88% of all deaths caused by cervical cancer 
1
occur in developing countries.  In sub-Saharan Africa, cervical cancer ranks the second most 
1,3
common cancer among women.  In the year 2012, out of the estimated 370,138 cancers in sub-
Saharan African women, about 93,200 new cases of cervical cancer (25.2% of cancers) were 
3
recorded.  The lowest burden of cervical cancer was reported in Australia, Northern America and 
1
Western Europe with an age-standardised incidence rate of 5.0, 5.7 and 6.9/100 000, respectively.  
The low incidence of cervical cancer in these regions has been attributed to the establishment of an 
effective cervical cancer screening programme. A strong correlation between the initiation of 
cytology screening and a reduction in the incidence and mortality from cervical cancer have been 
4,5
demonstrated in countries like Denmark, Finland, Iceland, Norway and Sweden.  The introduction 
of these screening modalities was based on the knowledge that invasive cervical cancer is preceded 
by an interval of epithelial dysplastic changes, typically occurring at the transformation zone. While 
1
the age-standardised incidence rate of cervical cancer in Nigeria has increased to over 30/100 000,  
much needs to be done to indigenize the experience from these successful screening programmes  
taking into cognizance the peculiarity of our environment.
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depend on past screening results. If previous 
tests have been negative, additional screening is 
not required. Negative tests in this case means 3 
consecutive negative cytology results or 2 
consecutive co-testing results in the past 5 
7years.  Women with a history of cervical 
intraepithelial lesions (CIN)2, 3, or 
adenocarcinoma must continue screening 
beyond age 65. In women with total 
hysterectomy and no history of CIN2 or higher, 
additional screening is not needed, but for those 
with high-grade lesions before hysterectomy, 
cytology screening should be continued every 3 
years for the next 20 years. This is because, the 
risk of developing vaginal cuff cancer even 
years later still exists. Meanwhile, the role of 
6HPV testing in this setting is unclear
In the United Kingdom, the NHS Cervical 
Screening Programme (NHSCSP) recommends 
an entry into the screening programme by age 
825. According to the NHSCSP,  cervical 
screening should take place between the ages of 
25 and 64, at intervals of three or five years 
depending on the woman's age. According to the 
8guideline,  women between ages 25 and 49 
should have cytology screening three yearly, 
while those between the ages of 50 and 64 
should be screened every five years. Only 
women with recent abnormal pap smear result 
or those who have not been screened since age 
50 should continue cytology screening beyond 
65years.  The NHSCP does not recommend the 
use of HPV testing for routine use.
The success of cervical cancer screening 
programme in most developed countries has 
been tied to a combination of several 
approaches, such as, education, advocacy, 
legislation, vaccination, screening, early 
diagnosis and treatment. In low- and medium-
income countries, there is however a 
considerable variation in their extent of 
9implementation of these measures.  In achieving 
the successes experienced in high-income 
countries, low-and-medium-income countries 
should produce a blueprint for national cancer 
control using a framework that is socially and 
10culturally sensitive
In 2002, the Society of Gynaecology and 
Obstetrics of Nigeria (SOGON) constituted an 
expert committee on the prevention of cervical 
11cancer.  The aim of this was to prepare a strategic 
plan for a National Cervical cancer prevention 
11program in Nigeria. According to this protocol,  
the entry age for cervical cancer screening in 
Nigerian women should be 30 years or two years 
after the first childbirth, and the screening 
interval should be every three years. Women who 
had a cytology screening should be managed 
according to the detected abnormality. 
Meanwhile, to maximize the participation of 
women, and to improve the efficiency of 
screening and treatment in our environment, it 
was proposed that women aged 30-64 years 
should have at least once in a life-time screening. 
11
For screening to be successful, the test must be 
affordable. Also, the screening test, diagnosis 
and treatment should be provided on-site, 
preferably all in one or two visits (to ensure wide 
9coverage).  This is rarely the case in our 
environment. The complex inputs of sample 
collection, processing, reading and reporting of 
smears and quality assurance which has 
contributed to the success of cytology screening 
in high income countries is lacking in our 
environment. Studies from cytology screening 
projects in low-and-medium income countries in 
South and Central America, over the last three 
decades, have yielded only limited success in 
12, 13preventing cervical cancer . Therefore, down-
102
Trop J Obstet Gynaecol, 31 (2), August 2014
staging cytology screening to visual inspection 
with acetic acid (VIA) triage and the use of 
'single-visit approach' becomes important to 
achieve a high coverage in our environment.
The 'single-visit approach' adopted by the expert 
11
committee  therefore entails treating VIA-
positive women, with no evidence of invasive 
cancer, by cryotherapy at the same screening 
session. The cost-effectiveness of this approach 
has been confirmed using computer-based 
models of a variety of cervical cancer screening 
strategies in India, Kenya, Peru, South Africa 
and Thailand. It was discovered that there was a 
reduction in the lifetime risk of cancer by about 
25%–36% and a reduction in the cost per year of 
14
life saved to <$500.  The “single-visit 
approach”; which can be implemented by 
midlevel providers, is justified in routine 
practice in low income countries, based on the 
available evidence of its safety, acceptability 
9
and effectiveness.  From a randomized trial in 
India, a 25% reduction in cervical cancer 
incidence and a 35% reduction in cervical 
cancer mortality were found following a single 
round of VIA screening provided by trained 
15
nurses.  It is however important to note that VIA 
is a subjective test that suffers from high false 
positive rates, low to moderate specificity and 
reproducibility, and the quality assurance 
procedures of this screening modality is yet to be 
9
standardized.
Treatment of Abnormal Screening Test
Screening is ineffective, if the detected pre-
clinical disease is not managed appropriately. 
Therefore, to reduce the incidence and mortality 
from cervical cancer, several working groups 
and expert committees, based on available 
scientific evidence, have arrived at consensus 
guidelines to guide practitioners on the 
m a n a g e m e n t  f o r  s c r e e n e d  c e r v i c a l  
abnormalities. 
Unsatisfactory cytology specimens are 
u n r e l i a b l e  f o r  d e t e c t i n g  e p i t h e l i a l  
16
abnormalities.  In most cases, they are as a 
17
result of insufficient squamous cells,  although 
when conventional Pap tests are employed, 
specimens can also be rendered unsatisfactory 
by obscuring blood, inflammation, or other 
18
processes.  According to the 2012 ASCCP 
16
Consensus Guidelines,  women with an 
unsatisfactory cytology result with negative or 
no HPV test result should have a repeat cytology 
in 2-4 months while correcting, when possible, 
the problem that caused the unsatisfactory 
smear. Treating the obscuring inflammation 
when a specific infection is present is important.  
For women who had a co-testing (combined 
cytology and HPV tests), and have a positive 
HPV test and unsatisfactory cytology test, either 
a repeat cytology in 2-4 months or colposcopy is 
acceptable. Invasive cancers do bleed on 
contact, it may also be associated with 
inflammatory processes. According to the 
8
NHSCSP guidelines,  women with persistent 
inadequate samples (after three consecutive 
inadequate samples)  should undergo 
colposcopy to exclude invasive cancer, as 
inadequate results may be associated with 
lesions that are not exfoliating.
Atypical Squamous Cell of Undetermined 
Significance (ASC-US) is the most common 
16
cytologic abnormality,  it represents a category 
of morphologic uncertainty. Thus HPV testing 
for the management of ASC-US cytology tests 
helps to objectively stratify the risk for the 
development of worse cervical cancer precursor 
6
lesions.  Despite this, ASCUS carries a low risk 
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for CIN 3+, partly because one third to two 
thirds of women with ASCUS have HPV-
19,20
negative test.
For women with ASC-US cytology, where HPV 
testing is possible, reflex HPV testing is 
16
preferred.  Alternatively, when there is no HPV 
result, a repeat cytology at 1 year would be 
16
acceptable.  For women with HPV-negative 
ASC-US, whether from reflex HPV testing or 
co-testing, repeat co-testing at 3 years is 
recommended while women with HPV-positive 
ASC-US, whether from reflex HPV testing or 
16
co-testing should have a colposcopy.  If 
colposcopy does not identify CIN, a repeat co-
testing at 12 months is recommended. In women 
with ASC-US cytology and no HPV result; after 
repeating cytology at 1 year, a result of ASC-US 
16
or worse is an indication for colposcopy.  
However, if the cytology result is normal, a 
return to cytology testing at 3-year intervals is 
16
recommended.
Atypical Squamous Cell cannot exclude 
HSIL (ASC-H) confers a higher risk for CIN 3+ 
over time than ASC-US or low-grade squamous 
21,22
intraepithelial lesion (LSIL),  although the 
risk is lower than that of high-grade squamous 
16
intraepithelial lesion (HSIL).  The high rate of 
HPV detection in women with ASC-H makes 
23
reflex HPV testing unsuitable.  In addition, the 
5-year cancer risk among HPV-negative women 
with ASC-H is 2%. This also is high to justify 
21
observation.  Therefore, in women with ASC-H 
cytology, colposcopy is recommended 
16
regardless of HPV result.  
Women with a result of LSIL cytology and 
positive HPV test on co-testing, and those with 
LSIL cytology with no HPV test should be 
16
referred for colposcopy.  However, those with a 
negative HPV test on co-testing should, 
preferably repeat co-testing after one year, 
although an immediate referral for colposcopy is 
16
acceptable.  If co-testing at 1 year shows normal 
cytology and negative HPV, the co-testing is 
repeated after 3 years. However, if co-testing 
result is either ASUS or worse, or HPV positive, 
16
colposcopy is recommended.  
According to the ASCCP guideline, women with 
no identifiable lesion on colposcopy and those 
with CIN 1 should have a co-test (cytology and 
HPV test) a year later. A normal cytology and 
HPV test, means that follow-up testing should be 
16
done 3 years later.  If CIN 1 persists for at least 2 
years, either a continued follow-up or treating 
with abalative or excisional technique is 
acceptable. An histology result of CIN2,3 is 
managed by either excisional or ablative 
16
techniques.
HSIL is associated with a high incidence of CIN 
2+ on colposcopy. CIN2+ is found in 60% of 
24,25,26
these women.  and this might justify an 
immediate excision of the transformation zone in 
16
those who are likely to be lost to follow-up;  as is 
the case in most developing countries.
For women with HSIL cytology, acceptable 
pathways of management are: colposcopy or 
16
immediate loop electrosurgical excision.  If 
colposcopy is the elected option and CIN2/3 
lesions were identified, both excision and 
ablation are acceptable treatment modalities. 
However, if CIN 2/3 is not identified, the women 
could either be observed by ensuring cytology 
16
and HPV testing after 12 and 24 months.  
Otherwise a diagnostic excision procedure 
16
would still be acceptable.  For women on 
observation, a diagnostic excision procedure is 
recommended when cytologic result is HSIL at 
16
either the 1-year or 2-year visit.  After treatment, 
co-testing should be done at 12 and 24 months. If 
both co-tests are negative, retesting in 3 years is 
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recommended. If all tests are negative, routine 
screening is recommended for at least 20 years, 
even if this extends screening beyond 65 years of 
16age.
An interpretation of Atypical Glandular Cell 
2 7(AGC)  is  poorly reproducible  and 
28uncommon . It has been associated with 
metaplasia, polyps and also neoplasias such as, 
adenocarcinomas of the endometrium, cervix, 
29ovary, fallopian tube.  Women with AGC-not 
otherwise specified (AGC-NOS) should have 
colposcopy with endocervical sampling, 
16regardless of their HPV result.  Those with CIN 
2/3 following colposcopic evaluation could 
either have an ablative or a diagnostic excisional 
procedure. If no CIN 2/3 was observed, co-
testing at 12 months and 24 months is 
16recommended,  and if both contests are 
negative, follow-up co-testing in 3 years is 
16recommended.  In the event of an abnormal 12 
or 24 month follow-up test, a colposcopy should 
be done. For women with AGC ''favor 
neoplasia'' (AGC-FN) or endocervical 
adenocarcinoma in-situ cytology, colposcopy 
wi th  endocervica l  sampl ing i s  a lso  
16 recommended, regardless of the HPV result.
Once an invasive disease has been ruled out 
during the initial colposcopic workup, a 
d i a g n o s t i c  e x c i s i o n a l  p r o c e d u r e  i s  
16recommended. 
Cytology screening programs have lead to a 
remarkable decline in the prevalence of cervical 
30cancer in developed countries.  This, however 
is not without a considerable financial, technical 
and logistic inputs, which often time is lacking 
in most low and medium income countries. The 
challenges and difficulties in implementing 
cytology screening in low-and-medium-income 
country have stimulated the search for 
alternative methods of screening such as visual 
inspection with acetic acid (VIA) or with 
31,32Lugol's iodine.
VIA is a useful alternative for low-resource 
settings, but standardized training and careful 
monitoring of test positivity and detection rates 
33 are essential to ensure optimal performance. It 
is a simple and inexpensive test, that can be 
provided by midwives, nurses and other health 
33 workers. Providers can be trained in 5-10days.
VIA does not require a laboratory infrastructure, 
and the consumables required for this procedure 
are cheap and are universally available. The test 
results are immediately available. This permits 
treatment with cryotherapy without additional 
recalls. 
Treatment with cryotherapy is done if the 
observed lesion does not extend into the 
endocervical canal or onto the vaginal walls, if 
no evidence of invasive cancer is present, and 
the lesion involves less than 3 quadrants of the 
transformation zone, provided the whole lesion 
could be covered by the cryoprobe.  Local 
anesthesia or analgesics are not required prior to 
33the procedure
Compared to cytology, VIA has a higher 
34sensitivity but lower specificity.  Its accuracy at 
detecting cervical neoplasia has been 
extensively studied and found to be 
34,35satisfactory.  Frequently repeated screening, 
although more effective, may not be feasible or 
may be too costly for implementation in most 
13low resource countries.  Therefore, a logical 
first step in low resource countries is to achieve a 
high level of coverage of the target population 
with a good-quality, highly sensitive test and 
good-quality treatment.
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